Cefazolin

Generic Name: Cefazolin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄N_₈O_₄S_₃

CAS Number: 25953-19-9

Unique Ingredient Identifier: IHS69L0Y4T

Background: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication: Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.

Associated Conditions: Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

The Effect of Bowel Preparation on Perioperative Bleeding

Phase 1

Completed

Conditions: Surgery

Interventions: Drug: placebo
Drug: PEG
Drug: Cefazolin

First Posted Date: 2015-07-10

Last Posted Date: 2015-07-10

Lead Sponsor: Isfahan University of Medical Sciences

Target Recruit Count: 105

Registration Number: NCT02493894

Locations: 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of

Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy

Phase 4

Completed

Conditions: Pleural Effusion
Empyema
Pleurisy

Interventions: Other: saline
Drug: Cefazolin

First Posted Date: 2015-05-18

Last Posted Date: 2017-01-18

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 100

Registration Number: NCT02446782

Locations: 🇮🇳
PGIMER, Chandigarh, India

Preoperative Antibiotic Dosing for Total Knee Arthroplasty

Phase 4

Withdrawn

Conditions: Acute Infection of Total Knee Replacement

Interventions: Device: New Intraosseous
Drug: Cefazolin

First Posted Date: 2015-05-05

Last Posted Date: 2017-07-28

Lead Sponsor: Duke University

Registration Number: NCT02433704

Locations: 🇺🇸
Duke Medical Plaza Page Road, Durham, North Carolina, United States

The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures

Not Applicable

Completed

Conditions: Prosthetic Joint Infection

Interventions: Other: Control group
Drug: Cefazolin

First Posted Date: 2015-04-09

Last Posted Date: 2016-08-03

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 28

Registration Number: NCT02413034

Penetration of Cefazolin Into Hepatic Cysts

Not Applicable

Completed

Conditions: Hepatic Cyst

Interventions: Other: Peripheral intravenous cannula (IVC)
Drug: cefazolin

First Posted Date: 2015-02-20

Last Posted Date: 2016-02-03

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 8

Registration Number: NCT02368015

Locations: 🇳🇱
Radboud University Nijmegen Medical Center; Department of Gastroenterology & Hepatology, Nijmegen, Gelderland, Netherlands

Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain

Phase 4

Conditions: Vitreoretinal Surgery
Endophthalmitis

Interventions: Drug: Cefazolin
Drug: Lidocaine

First Posted Date: 2014-12-24

Last Posted Date: 2014-12-24

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 54

Registration Number: NCT02324166

The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Bupivacaine
Drug: Morphine
Drug: Methylprednisolone
Drug: Cefazolin
Drug: Normal saline
Drug: Midazolam
Drug: Propofol
Drug: Dexamethasone
Device: 8 MHz. Chiba needle, 22 G / 4 inches

First Posted Date: 2014-11-17

Last Posted Date: 2019-01-11

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 111

Registration Number: NCT02292082

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Prevention of Infections in Cardiac Surgery

Not Applicable

Active, not recruiting

Conditions: Thoracic Surgery
Antibiotic Prophylaxis

Interventions: Drug: Cefazolin
Drug: Vancomycin

First Posted Date: 2014-11-06

Last Posted Date: 2023-09-22

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 3000

Registration Number: NCT02285140

Locations: 🇨🇦
Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦
Jewish Hospital, Montréal, Quebec, Canada

and more 1 locations

Checklist to Prevent MRSA Surgical Site Infections

Not Applicable

Completed

Conditions: Surgical Site Infection

Interventions: Drug: Mupirocin
Drug: Chlorhexidine gluconate
Drug: Cefazolin
Drug: Vancomycin
Drug: Nasal Povidone Iodine

First Posted Date: 2014-08-13

Last Posted Date: 2021-03-11

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 1794

Registration Number: NCT02216227

Locations: 🇺🇸
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland, United States
🇺🇸
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States
🇺🇸
VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States

and more 8 locations

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Phase 3

Terminated

Conditions: Bacteremia

Interventions: Drug: Vancomycin
Drug: Telavancin
Drug: Daptomycin
Drug: Synthetic penicillin
Drug: Cefazolin

First Posted Date: 2014-08-04

Last Posted Date: 2020-02-17

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 121

Registration Number: NCT02208063

Locations: 🇺🇸
Remington-Davis Clinical Research, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy